Convatec welcomes the postponement of Local Coverage Determinations (LCDs) on skin substitutes in the United States

London, UK, 26 January 2025 - Convatec, a leading medical products and technologies company, welcomes the postponement of the future effective date of the Medicare Administrative Contractors (MACs) Local Coverage Determinations (LCDs) for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs).

Healthcare professionals (HCPs) and patients have reported significant clinical benefits from the use of InnovaMatrix^®. Convatec believes Medicare patients and their HCPs should continue to have the choice of full access to InnovaMatrix^® for all wound types. 

The revised future effective date, currently 13 April 2025, means that Medicare patients with DFUs and VLUs will continue to benefit from InnovaMatrix^® technology. We are committed to working collaboratively with the new US Administration, including at the Centers for Medicare & Medicaid Services (CMS), and their contractors, in the best interests of patients.

Notes to editors

Convatec is committed to evidence-based medicine to improve outcomes for patients and choice for HCPs. We continue to develop our clinical evidence and in October 2024, we published an update on both of the randomised controlled trials (RCTs) we have initiated on InnovaMatrix^® in diabetic foot ulcers and venous leg ulcers. These are on track to report in 2026, and we will provide periodic updates on their progress. This will complement our published real-world evidence (RWE), including RWE published in December 2024.

Convatec’s InnovaMatrix^® is a leading porcine placental-derived extra-cellular matrix for treatment of chronic, surgical and trauma wounds. The product is cleared by the US Food and Drug Administration (FDA) in 15 separate medical indications under a 510k medical device licence. Patients and HCPs have experienced first-hand the positive, sometimes limb-saving, impact that InnovaMatrix^® products have on chronic wounds. 

Contact
Investor Relations: IR@convatec.com   
Media: MediaRelations@convatec.com

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2023 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com